11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
June 2025 in “Journal of medical and dental science research.” i-PRF and A-PRF show promise in promoting hair regrowth and improving scalp health in androgenetic alopecia.
87 citations
,
February 2019 in “Tissue Engineering Part B Reviews” Platelet-rich plasma can effectively treat and prevent tissue infections.
20 citations
,
January 2016 in “Intractable & Rare Diseases Research” Combination therapy, especially with finasteride, is effective for treating frontal fibrosing alopecia.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
January 2016 in “Chemistry & Industry” Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
11 citations
,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
March 2017 in “Current dermatology reports” Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
Newly designed proteins can effectively degrade specific proteins in cells, offering a potential new therapy method.
42 citations
,
January 2019 in “Frontiers in Immunology” A blood pressure drug, diltiazem, may also help treat influenza.
September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
1 citations
,
April 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors are effective treatments for alopecia areata.
February 2025 in “Archives of Dermatological Research” Injectable platelet-rich fibrin effectively improves hair density and scalp symptoms in androgenetic alopecia.
4 citations
,
July 2018 in “PubMed” Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
28 citations
,
February 1999 in “Journal of Investigative Dermatology” Urokinase, a type of protein, helps skin cells multiply faster, especially in newborn mice.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
July 2024 in “Bozok Tıp Dergisi” Platelet-rich plasma treatment shows early improvement in femur head avascular necrosis.